OPEN ACCESS Freely available online

Angiology: Open Access

Short Communication

Venous Thromboembolism: Etiology, Risk Factors, and Prevention Strategies

Braakman Danielle*

Department of Cardiovascular Surgery, Central University, Accra, Ghana

DESCRIPTION

Venous Thromboembolism (VTE) stands as a critical medical condition characterized by the formation of blood clots within the venous system, commonly described as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) [1]. This condition causes a significant global health burden, contributing to morbidity and mortality across diverse patient populations. Understanding the pathophysiology, risk factors, and clinical implications of VTE is essential for its timely diagnosis, effective management, and prevention of potentially life-threatening complications [2].Additionally, advancements in diagnostic imaging techniques, such as Doppler ultrasound and computed tomography pulmonary angiography, have revolutionized the detection of VTE, enabling prompt intervention. Collaborative efforts among healthcare professionals, including physicians, nurses, and pharmacists, plays an important role in implementing evidence-based guidelines for VTE management and prophylaxis. Furthermore, emerging research in the field of thrombosis creates an impact on novel therapeutic targets and personalized approaches to VTE prevention, promotes improved cardiac health in the future [3,4].

Etiology of venous thromboembolism

Venous thromboembolism arises from the interaction of three key factors known as "Virchow's triad".

Alterations in blood flow: Prolonged immobilization, such as during long-haul flights or hospitalization, can lead to venous stasis, promoting thrombus formation. Conditions that prone to venous return, such as congestive heart failure or obesity, contribute to venous stasis and increase the risk of VTE.

Vascular endothelial injury: Endothelial damage resulting from trauma, surgery, or inflammation initiates the coagulation cascade and promotes thrombus formation. Activating venous catheters or intravenous drug use can cause endothelial injury, predisposing individuals to VTE.

Hypercoagulability: Imbalance in procoagulant and anticoagulant factors, either inherited or acquired, leads to a hypercoagulable state. Genetic mutations such as factor V Leiden or prothrombin gene mutation increase the risk of VTE, as do acquired conditions like cancer or antiphospholipid syndrome [5].

Risk factors for venous thromboembolism

Acute medical illness: Hospitalized patients with acute medical conditions, such as heart failure or respiratory infections, have an increased risk of VTE due to immobility and underlying prothrombotic factors.

Surgical procedures: Major surgeries, particularly orthopedic and abdominal procedures, are associated with a higher risk of VTE due to endothelial injury, venous stasis, and systemic inflammatory response [6].

Cancer: Malignancy increases the risk of VTE through various mechanisms, including tumor-related procoagulant factors, compression of vessels by tumor mass, and effects of chemotherapy.

Pregnancy and postpartum period: Pregnancy and the postpartum period are hypercoagulable states due to hormonal changes, venous stasis, and endothelial injury, exposing women to VTE.

Hormonal therapy: Estrogen-containing contraceptives and hormone replacement therapy increase the risk of VTE, particularly in women with additional risk factors such as smoking or obesity.

Inherited thrombophilias: Genetic mutations affecting coagulation factors or anticoagulant proteins, such as factor V Leiden or protein C deficiency, confer an increased risk of VTE.

Age and immobility: Advancing age and prolonged immobility, whether due to hospitalization, travel, or sedentary lifestyle, are independent risk factors for VTE.

Other risk factors: Obesity, smoking, inflammatory conditions, and prior history of VTE further elevate the risk of thromboembolic events [7,8].

Correspondence to: Braakman Danielle, Department of Cardiovascular Surgery, Central University, Accra, Ghana, E-mail: braakmandanielle@hotmail.com

Received: 23-Feb-2024, Manuscript No. AOA-24-30946; **Editor assigned:** 27-Feb-2024, PreQC No.AOA-24-30946 (PQ); **Reviewed:** 12-Mar-2024, QC No. AOA-24-30946; **Revised:** 19-Mar-2024, Manuscript No. AOA-24-30946 (R); **Published:** 26-Mar-2024, DOI: 10.35841/2329-9495.24.12.445.

Citation: Danielle B (2024) Venous Thromboembolism: Etiology, Risk Factors, and Prevention Strategies. Angiol Open Access. 12:445.

Prevention strategies for venous thromboembolism

Pharmacological prophylaxis: Administration of anticoagulant medications, such as Low Molecular Weight Heparin (LMWH) or Unfractionated Heparin (UFH), reduces the risk of VTE in high-risk settings, including hospitalized patients undergoing surgery or with acute medical illness [9].

Mechanical prophylaxis: Intermittent pneumatic compression devices or graduated compression stockings promote venous blood flow and reduce stasis, particularly in patients at high risk of bleeding or with contraindications to anticoagulation.

Enhanced recovery protocols: Early ambulation, optimization of perioperative care, and multimodal pain management strategies minimize the risk of VTE in surgical patients.

Lifestyle modifications: Encouraging regular physical activity, smoking cessation, weight management, and hydration promotes vascular health and reduces the risk of VTE in the general population.

Individualized risk assessment: Risk stratification tools, such as the padua prediction score or caprini risk assessment model, help identify patients at highest risk of VTE, enabling targeted prophylactic interventions [10].

CONCLUSION

Venous Thromboembolism (VTE) poses a significant clinical challenge, necessitating a comprehensive understanding of its pathophysiology, risk factors, and preventive strategies. Timely diagnosis and effective management are important for reducing morbidity and mortality associated with this condition. Through the integration of evidence-based interventions, including pharmacological and mechanical thromboprophylaxis, lifestyle modifications, and personalized risk assessment, healthcare providers can mitigate the burden of VTE and enhance patient outcomes. However, ongoing research efforts are enhanced to further elucidate the complexities of VTE and identify novel therapeutic targets. By promoting interdisciplinary collaboration and implementing targeted preventive measures, reduces the incidence of VTE-related complications and improving the overall quality of care for affected individuals.

REFERENCES

1. Di Nisio M, van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060-3073.
2. National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: Reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline (NG89). 2018.
3. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J Thromb Haemost. 2010;8(11): 2450-2457.
4. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, et al. Thrombosis: A major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363-2371.
5. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800.
6. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474.
7. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2S):e195S-e226S.
8. Liew A, Douketis J. Clinical approach to venous thromboembolism prevention in cancer. Thromb Res. 2018;164(Sl):S19-S26.
9. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
10. Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, et al. Inferior cena cava filters to prevent pulmonary embolism: Systematic review and meta-analysis. J Am Coll Cardiol. 2017;70(13):1587-1597.